Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Outcome Of Tacrine Therapy Depends On Apolipoprotein Genotype And Gender Of The Subjects With Alzheimer's Disease

M. Farlow, D. Lahiri, J. Poirier, J. Davignon, L. Schneider, S. Hui
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double-blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ϵ2-3 as theϵ4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p< 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ϵ2-3 compared with ϵ4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ϵ2-3 andϵ4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.
This paper references
10.1016/0022-3956(75)90026-6
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
(1975)
Clinical Global Assessment scale (CGI). ECDEU assessment manual for psychopharmacology
B Reisberg (1976)
10.1016/0304-3940(77)90070-2
A cholinergic connection between normal aging and senile dementia in the human hippocampus
E. Perry (1977)
10.1126/SCIENCE.7058341
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.
P. Whitehouse (1982)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
10.1176/AJP.141.1.1
Genesis and evolution of behavioral disorders: from infancy to early adult life.
Alan Thomas (1984)
10.1176/AJP.141.11.1356
A new rating scale for Alzheimer's disease.
W. G. Rosen (1984)
10.1007/978-1-4684-5847-3_70
Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.
F. Hefti (1989)
10.1073/PNAS.89.1.1
Expression cloning of a Na(+)-independent neutral amino acid transporter from rat kidney.
Suresh S. Tate (1992)
10.1001/JAMA.1992.03490180055026
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
M. Farlow (1992)
10.1073/PNAS.89.23.11471
Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.
N. Holford (1992)
10.1016/0140-6736(93)91705-Q
Apolipoprotein E polymorphism and Alzheimer's disease
J. Poirier (1993)
10.1016/0306-4522(93)90456-P
Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats
J. Poirier (1993)
10.1016/0140-6736(93)91879-Q
Vitamin A supplementation in northern Ghana: effects on clinic attendances, hospital admissions, and child mortality
G. V. S. Team (1993)
10.1212/WNL.43.8.1467
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
A. Saunders (1993)
10.1016/0140-6736(93)91878-P
Ischaemic preconditioning: can the protection be bottled?
M. Cohen (1993)
10.1126/SCIENCE.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
10.1212/WNL.43.1_Part_1.1
Neurosurgical horizons in Parkinson's disease
C. Goetz (1993)
10.1073/PNAS.90.17.8098
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
W. Strittmatter (1993)
10.1016/0166-2236(94)90156-2
Apolipoprotein E in animal models of CNS injury and in alzheimer's disease
J. Poirier (1994)
10.1126/SCIENCE.8171342
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.
B. Nathan (1994)
10.1016/0304-3940(94)90385-9
APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease
C. Broeckhoven (1994)
10.1002/ANA.410360614
Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies
J. Nalbantoglu (1994)
10.1016/0304-3940(94)90342-5
The role of dopamine D1-receptors in morphine-induced hyperlocomotion in mice
M. Funada (1994)
Gracon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
M J Knapp (1994)
Tacrine alters the processing of beta-amyloid precursor protein in cell lines
D K Lahiri (1994)
10.1001/JAMA.1995.03520400044042
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
R. Petersen (1995)
10.1002/ANA.410380515
Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives
L. Farrer (1995)
10.1002/ANA.410370509
Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease
G. Frisoni (1995)
10.1073/PNAS.92.1.1
Chemical ecology.
T. Eisner (1995)
10.1002/ANA.410370104
Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis
J. Whitaker (1995)
10.2165/00023210-199504020-00004
Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease
L. Schneider (1995)
10.1073/PNAS.92.26.12260
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
J. Poirier (1995)
The apolipoprotein E €4 allele and sex-specific risk of Alzheimer’s disease
EH Corder (1995)
10.1038/NG0996-5
Alkaptonuria: such a long journey
C. Scriver (1996)
10.1038/ng0996-55
Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides
M. Miyata (1996)
10.1212/WNL.46.1.1
A new look and feel
R. Daroff (1996)
Apolipoprotein E €4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease
A Kurz (1996)
Progress in molecular genetic of Alzheimer’s disease
FM Hisama (1996)



This paper is referenced by
10.1002/prm2.12036
Precision health in Alzheimer disease: Risk assessment‐based strategies
Jihan Azar (2021)
10.3389/fneur.2021.576366
Considering Biological Sex in Traumatic Brain Injury
A. Biegon (2021)
10.1016/b978-0-12-819344-0.00013-2
Sex and gender differences in genetic and lifestyle risk and protective factors for dementia
Shireen Sindi (2021)
10.2174/1568026620666200422105156
Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine.
M. Kabir (2020)
10.1080/17425255.2020.1779700
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
R. Cacabelos (2020)
10.1016/b978-0-12-813955-4.00006-4
Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease
J. Poirier (2020)
10.3233/JAD-180995
Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer's Disease.
J. Brandt (2019)
10.1111/jcmm.13852
Molecular differences in Alzheimer's disease between male and female patients determined by integrative network analysis
Lin-lin Sun (2018)
10.1038/s41598-019-48238-6
M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera
Arpita Konar (2019)
10.3389/fnagi.2019.00315
Sex and Gender Driven Modifiers of Alzheimer’s: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks
A. Rahman (2019)
10.1159/000490175
Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Ying-Chih Cheng (2018)
10.1038/s41582-018-0032-9
Sex differences in Alzheimer disease — the gateway to precision medicine
M. Ferretti (2018)
10.3233/JAD-180450
Effectiveness of a Personalized Brain-Computer Interface System for Cognitive Training in Healthy Elderly: A Randomized Controlled Trial.
S. Yeo (2018)
10.1016/j.phrs.2016.11.035
Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials
M. Canevelli (2017)
10.1038/srep29364
Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer’s disease in vitro
S. Ghura (2016)
10.1016/B978-0-12-410529-4.00004-8
Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents
J. Poirier (2015)
10.2147/DNND.S41721
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
M. Kotze (2015)
10.1016/j.bbr.2014.10.033
Reference and working memory deficits in the 3xTg-AD mouse between 2 and 15-months of age: A cross-sectional study
Leanne M. Stevens (2015)
10.3109/03602532.2015.1047027
Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases
Renu Chaudhary (2015)
10.3233/JAD-142589
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
J. Waring (2015)
10.1111/jnc.13072
APOE‐modulated Aβ‐induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective
L. Tai (2015)
10.1097/WAD.0b013e318299d096
The Effect of APOE &egr;4 Allele on Cholinesterase Inhibitors in Patients With Alzheimer Disease: Evaluation of the Feasibility of Resting State Functional Connectivity Magnetic Resonance Imaging
L. Wang (2014)
10.3389/fnagi.2014.00154
The potential applications of Apolipoprotein E in personalized medicine
S. Villeneuve (2014)
10.1016/B978-0-12-411464-7.00021-3
Application of Pharmacogenomics in Global Alzheimer’s Disease Clinical Trials and Ethical Implications
S. Spector (2014)
10.2174/1567205011666140130152114
Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.
H. B. Yoo (2014)
Activity Modulate Retinoid X Receptor Agonist Genotype APOE Pathology and β Amyloid-Molecular Bases of Disease :
J. Ladu (2014)
10.1074/jbc.M114.600833
Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo*
L. Tai (2014)
10.1097/NMD.0000000000000107
Cognitive Subdomain Responses to Galantamine in Alzheimer’s Disease
J. Song (2014)
10.1371/journal.pone.0054713
Accelerated Cell Aging in Female APOE-ε4 Carriers: Implications for Hormone Therapy Use
Emily G. Jacobs (2013)
10.1016/j.neurobiolaging.2013.04.018
Reduced plasticity and mild cognitive impairment-like deficits after entorhinal lesions in hAPP/APOE4 mice
Jean-Bastien Bott (2013)
10.1016/J.DDSTR.2013.05.003
Personalized medicine in context: social science perspectives
R. Tutton (2013)
10.1007/s11682-013-9272-x
Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction
Leo Ungar (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar